Hemogenyx Pharmaceuticals (HEMO)

Sector:

Pharma and Biotech

339.50p
   
  • Change Today:
    -8.00p
  • 52 Week High: 1,582.00
  • 52 Week Low: 320.00
  • Currency: UK Pounds
  • Shares Issued: 3.60m
  • Volume: 7,700
  • Market Cap: £12.24m
  • RiskGrade: 340

Hemogenyx shares boosted by partner investment

By Benjamin Chiou

Date: Wednesday 02 Oct 2024

LONDON (ShareCast) - (Sharecast News) - Shares in Hemogenyx Pharmaceuticals jumped on Wednesday after the clinical-stage biopharmaceutical group announced another investment from Prevail Partners via a share subscription at a significant premium to the current market value.
Investment fund Prevail Partners agreed to invest $350,000 (£269,000) through a subscription priced at $0.075 (5.6p) per share.

The subscription, which will take effect next March, followed a similar investment by the same fund last month, and comes at a 275% premium to Hemogenyx's closing price of 1.61p on Tuesday.

The investment comes ahead of Hemogenyx's planned HEMO-CAR-T pediatric study, in which Prevail Partners affiliate Prevail InfoWorks will act as clinical research organisation.

"As we seek to bring the curative power of cell therapies to children suffering from the otherwise largely incurable life-threatening diseases, AML and ALL, we are very confident in Prevail InfoWorks' ability to coordinate our Phase I clinical trial in pediatric relapsed/refractory AML and ALL," said Hemogenyx chief executive and co-founder Vladislav Sandler.

"Prevail Partners' strategic investment in the company, once again at a price very substantially above the company's existing share price, demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study."

The stock was up 5.4% at 1.69p by 1239 BST, briefly surging to a high of 3.0p earlier on.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HEMO Market Data

Currency UK Pounds
Share Price 339.50p
Change Today -8.00p
% Change -2.30 %
52 Week High 1,582.00
52 Week Low 320.00
Volume 7,700
Shares Issued 3.60m
Market Cap £12.24m
RiskGrade 340

HEMO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
44.19% below the market average44.19% below the market average44.19% below the market average44.19% below the market average44.19% below the market average
62.5% below the sector average62.5% below the sector average62.5% below the sector average62.5% below the sector average62.5% below the sector average
Price Trend
85.9% below the market average85.9% below the market average85.9% below the market average85.9% below the market average85.9% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Income Not Available
Growth Not Available

HEMO Dividends

No dividends found

Trades for 10-Feb-2025

Time Volume / Share Price
15:47 2 @ 344.00p
16:20 3 @ 340.00p
15:47 2 @ 344.00p
15:30 400 @ 335.60p
14:11 92 @ 335.50p

HEMO Key Personnel

CEO Vladislav Sandler Ph.D.

Top of Page